а) Research into the effect of the pyramid field on human lymphoblastoid cells. Source of the pyramid field was pyramid-field-structured water used to prepare the nutrient solution.
Cell viability was determined by staining with 0.4% tripan blue (Serva, Germany) and MTT (Sigma, USA) with spectrophotometry of the absorption of the vital dye.
As early as the 10th day of the experiment there began a noticeable (several fold) increase in cell count and cell-viability percentage in the treated sample compared to the control.
Data was obtained on the stimulating effect of a nutrient medium prepared with water exposed to a pyramid field on the viability and proliferation of human cells
An increase in cell life and viability over the control was found. As such, on the 11th day of the experiment these figures were 1.2 million/ml and 52% respectively for the control and 1.4 million/ml and 88% for the experiment; on the 21st day 0.05 million/ml and 2% for the control, and 0.3 million/ml and 49% for the experiment.
b) Ibid. a study was conducted into the effect of the pyramid field on the antiviral activity of immunoglobulin.
The object of the study was venoglobulin — human polyvalent immunoglobulin for intravenous injection, lyophilized (from Pasteur-Mérieux, France) on a culture of human diploid fibroblast cells. To determine the antiviral activity of the immunoglobulin (Ig), the encephalomyocarditis mouse virus (EMC virus) was used.
The antiviral activity of the drug was assessed by its ability to protect human cells from the cytopathic effect of the virus.
The venoglobulin was dissolved in distilled water in accordance with the instructions to a concentration of 50 μg/ml. In the study the drug was tested at two concentrations: 50 μg/ml and 0.5 μg/ml. Aliquots of both concentrations were exposed to a pyramid field. 24 hours prior to infection with the virus, the venoglobulin was introduced into cell cultures.
The EMC virus replicates well in diploid cultures of human fibroblasts, producing a pronounced cytopathic effect — the infectious titre of the virus reached 5.0 lg CPD50.
Venoglobulin at the concentration of 50 μg/ml significantly inhibited the multiplication of the virus — its titre reached only 2.0 lg TCPD50 (an inhibition factor of 3.0 lg). In the 100-fold reduced concentration of the preparation, a protective effect could no longer be detected.
A very different picture was observed when using venoglobulin preparations of the same concentrations but exposed to a pyramid field. In this case the preparation at a concentration of 50 μg/ml inhibited the reproduction of the EMC virus by 4.0 lg. Most significant, however, was that the preparation at a concentration of 0.5 μg/ml had the same inhibiting effect.
Thus, venoglobulin at a concentration of 0.5 μg/ml that had had no protective effect on the cells, after pyramid field exposure possessed a more pronounced virus-inhibiting effect than in the 100-fold more concentrated form of this drug.
Under further dilution, to concentrations of 0.005 μg/ml and 0.00005 μg/ml with subsequent pyramid field exposure, the venoglobulin displayed a pronounced anti-viral effect — the titre of the EMC virus reached only 1.0 lg TCPD50.
The anti-viral activity of the venoglobulin practically ceased to depend on its concentration.